Propeller Health received clearance from the U.S. Food and Drug Administration on its Propeller platform for use with GlaxoSmithKline’s Ellipta inhaler, the company announced today.

“Today, we are pleased to announce the FDA clearance of the Propeller platform for use with GSK’s Ellipta inhaler,” Propeller CEO David Van Sickle said in a statement. “Inclusion of GSK’s Ellipta inhaler in Propeller’s digitally guided therapy platform is an important step in our goal of modernizing the management of respiratory disease.”

According to a release, the Ellipta inhaler is the pharmaceutical company’s patented, dry powder inhaler, which will help physicians better understand asthma and COPD.

The clearance marks the eighth FDA clearance received by Propeller.